Compared with the control group, the SGLT2 inhibitors group demonstrated significantly lower risks of CIN (RR: 0.55, 95% CI: 0.41–0.73, P < .0001), all-cause mortality (RR: 0.49, 95% CI: 0.29–0.81, P = .005), MACE (RR: 0.33, 95% CI: 0.17–0.65, P = .01), and HF readmission (RR: 0.30, 95% CI: 0.16–0.56, P = .0001). This evidence concerns the gene SLC5A2 and hydrops fetalis.